Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | HPN | P05981 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064697 | 0.83 | ALOX15 (0.46) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL6768868 | 0.74 | CYP1A2 (0.45) | SMN1; SMN2ALDH1A1POLBTYRCYP2C9 | |
| SCHEMBL7722354 | 0.72 | CA2 (0.39) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL7730218 | 0.72 | ALOX15 (0.43) | PTGS1PTGS2MAPTALOX15 | |
| SCHEMBL15173818 | 0.70 | CA2 (0.59) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL10977187 | 0.70 | CA2 (0.48) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL13400274 | 0.67 | SMN1; SMN2 (0.54) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL17344317 | 0.67 | — | — | |
| SCHEMBL392804 | 0.66 | SMN1; SMN2 (0.52) | SMN1; SMN2CA2ALDH1A1POLBTYR | |
| SCHEMBL1882430 | 0.66 | SMN1; SMN2 (0.52) | SMN1; SMN2CA2ALDH1A1POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1631363-A | Preventive/remedy for xanthomatosis | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20030195246-A1 | Seamless soft capsule preparations containing dihydrobenzofuran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1314424-A1 | SEAMLESS SOFT CAPSULE PREPARATIONS CONTAINING DIHYDROBENZOFURAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-6440999-B1 | Intimal thickening inhibitory agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-27 | — | — | US | disclosed |
| US-6417225-B1 | HYDROQUINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-09 | — | — | US | disclosed |
| US-6156793-A | Prophylactic/therapeutic agents for atherosclerosis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133279-A | A 2,6-DI-T-BUTYLPHENOL DERIVATIVE FOR RENAL DISEASES, E.G., CHRONIC RENAL FAILURE, DIABETIC NEPHROPATHY GLOMERULAR NEPHRITIS, IMMUNOCOMPLEX NEPHRITIS AND ACUTE RENAL FAILURE; CYTOPROTECTIVE AGENT THAT INHIBITS THE LIPID PEROXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6103753-A | ADMINISTERING TO A PATIENT FOR INHIBITING THICKENING OF VASCULAR STENOSIS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, A 2,6-DI-T-BUTYLPHENOL DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-15 | — | — | US | disclosed |
| CN-1255058-A | Preventive/therapeutic agent for arteriosclerosis | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2000-05-31 | — | — | CN | disclosed |
| EP-0982029-A1 | PREVENTIVES/REMEDIES FOR ARTERIOSCLEROSIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-03-01 | — | — | EP | disclosed |
| EP-0950405-A1 | REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0665208-B1 | 4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-01-13 | — | — | EP | disclosed |
| CN-1204259-A | Intimal thickening inhibitor | SHONAN KIKO K K (JP) | 1999-01-06 | — | — | CN | disclosed |
| EP-0868913-A1 | INTIMAL THICKENING INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5663373-A | ANTIISCHEMIC AGENTS AND ANTIOXIDANTS FORMED IN MULTISTAGE REACTION WITH GRIGNARD REAGENT WITH ALDEHYDE, DISSOLVING, ACIDIFICATION, DEPROTECTION AND CYCLIZATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-09-02 | — | — | US | disclosed |
| US-5606089-A | ANTIISCHEMIC AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5574178-A | CHEMICAL INTERMEDIATES FOR OXIDATION RESISTANCE AND ANTIISCHEMIC AGENTS FORMED BY MULTISTAGE CYCLIZATION OF ALDEHYDE-ALCOHOL | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0665208-A1 | 4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195246-A1 | Seamless soft capsule preparations containing dihydrobenzofuran derivatives | CYP2D6, CYP2F1, SULT2A1 | SMN1; SMN2 2650/4885CA2 3737/4885ALDH1A1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.